Introduction
============

Chordoma and chondrosarcoma are rare, slow-growing malignant tumors. Chordoma originates from notochordal remnants [@B1], [@B2]. The annual incidence of chordoma is 0.1 per 100 000 individuals [@B2]. The most common site of chordoma is at the sacrococcygeal region (50%), followed by the skull base (30-35%) and the mobile spine (15-20%) [@B2], [@B3]. Chondrosarcoma accounts for 10-20% of all malignant bone tumors [@B4], [@B5]. The annual incidence of chondrosarcoma is about 0.2/100 000 [@B6]. Chondrosarcoma often occurs in the pelvis, femur, and humerus [@B5]. Surgical resection remains the mainstay treatment for these two diseases. Complete radical resection of the tumor ensures longer local control (LC) and disease-free survival compared with partial resection [@B7]-[@B9]. However, anatomical complexity, large tumor size, and high complication rates make it rarely possible to achieve R0 resection of these tumors [@B1], [@B5], [@B10]. Thus, combining radiotherapy and surgery appears promising. Higher local control rates of primary chordoma or chondrosarcoma are reported in patients who received resection combined with radiotherapy compared with resection only [@B11]-[@B13]. However, the majority of chordoma and chondrosarcoma are resistant to conventional photon therapy [@B14]-[@B17].

To overcome the challenge posed by the intrinsic radio-resistance, particle therapy, especially carbon ions, has received considerable attention. Carbon ions provide higher linear energy transfer (LET) and relative biological effectiveness (RBE). This enhanced RBE is driven by a unique DNA damage signature characterized by clustered lesions that overwhelm the DNA repair capacity of tumor cells [@B18]. In addition, carbon ion beams produce the Bragg Peak, which is the release of enormous energy at the end of their range [@B19], allowing for the maximum destructive energy to be deposited at tumor site while minimizing the damage to the adjacent normal tissues along their path [@B20], [@B21]. These biological and physical characteristics make carbon ion radiotherapy (CIRT) more advantageous than conventional photon radiotherapy in treating chordoma and chondrosarcoma [@B5], [@B7], [@B9], [@B22], [@B23].

As the morbidity of chordoma and chondrosarcoma is low, it will take long time to complete a prospective randomized controlled trial of conventional photon radiotherapy, let alone prospective trials of CIRT. Moreover, very little data about the role of CIRT in treating these tumors has been published. In order to improve the management of these rare diseases, publication of more information is essential. Particle therapy started at Shanghai Proton and Heavy Ion Center (SPHIC) in 2014. Until May 2018, more than 1200 cancer patients (including patients with chordoma or chondrosarcoma) have been treated with particle therapy at our center. In this study, we retrospectively evaluated the efficacy and safety of patients with extracranial chordoma or chondrosarcoma treated by CIRT.

Patients and Methods
====================

Patients
--------

This retrospective study was approved by our institutional review board (approval number, 180620EXP-01). All the patients gave written informed consent for CIRT as well as for future anonymous use of their clinical data. Patients who met the following criteria were included in this study: 1. histologically confirmed extracranial chordoma or chondrosarcoma without metastases; 2. Karnofsky Performance Status (KPS) ≥70; 3. a grossly measurable tumor; 4. no active concomitant malignancy; 5. completed CIRT at our center. Finally, a total of 21 consecutive patients were enrolled in this study.

Treatment planning
------------------

To immobilize the patients, an individual vacuum bag and a body mask were used. A CT, without contrast enhancement, was acquired in the treatment position for planning (2 mm slice thickness). To accurately delineate the target volumes and organ at risk (OAR), contrast-enhanced MRI was performed. The target volumes and OAR were delineated through the Siemens Syngo RT planning system (Siemens Healthcare, Erlangen, Germany). The gross tumor volume (GTV) included the visible tumor on the CT and MRI. A 5-mm margin around the GTV was defined as the clinical target volume for the boost dose (CTVboost). The clinical target volume for the primary plan (CTV) was established as a 5-mm margin around the CTVboost. The planning target volume (PTV) was defined as the CTV plus 5-10 mm allowing for setup variability and an internal margin where necessary. All the treatment plans consisted of 2-4 active scanning beams.

The doses were measured by gray equivalent (GyE, defined as carbon ion physical dose multiplied by RBE value). As shown in Table [1](#T1){ref-type="table"}, the median prescribed dose to CTVboost was 69 GyE (range: 57-80 GyE). For the patients with sacrococcygeal or pelvis tumor, the dose constraints on the bowel were D-max (maximum dose) \<60 GyE; the dose constraints on the rectum were D-max \<66 GyE, V~60~ (volume receiving ≥60 GyE) \<1 ml, V~50~ (volume receiving ≥50 GyE) \<10%, and V~30~ (volume receiving ≥30 GyE) \<25%. For the patient with tumor at thoracic vertebra, the dose constraints on the lung, heart, and spinal cord were V~20~ (volume receiving ≥20 GyE) \<20%, D-mean (mean dose) \<5 GyE, and D-max \<40 GyE, respectively. The dose constraints on the OAR were set at 70% for the patients who received previous photon radiotherapy, disregarding the interval between the two courses of radiotherapy.

Follow-up and Statistics
------------------------

The follow-up period was counted from the first day of the CIRT course. To closely monitor these patients, the follow-up examinations were performed every 3 months in the first two years and every 6 months in the following years. The follow-up examinations included physical examinations, a MRI with contrast enhancement, a chest CT, and abdominal ultrasonography. The treatment efficacy was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [@B24]. Early toxicities, which were defined as side effects occurring within 3 months after the initiation of CIRT, were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.03. Adverse events that occurred 3 months after the initiation of CIRT were considered as late toxicities. The late toxicities were graded using the Radiation Therapy Oncology Group (RTOG) criteria [@B25].

The local control (LC), progression free survival (PFS), and overall survival (OS) rates were evaluated using the Kaplan-Meier method. The LC rate was defined as the time from the initiation of CIRT to local progression. The PFS was calculated as the time from the initiation of CIRT to local progression, distant metastasis or death due to any cause. The OS was defined as the time from the initiation of CIRT to death due to any cause. The association between each of the candidate prognostic factors and the estimated LC, PFS or OS was tested using the log rank test. The candidate prognostic factors included age, metal implant status, treatment status, sex, dose, and GTV. A two-sided *p* ≤0.05 was considered statistically significant. All the analyses were performed using R (version 3.3.1).

Results
=======

Patients
--------

This retrospective study analyzed data of 21 consecutive patients with histologically confirmed chordoma (n=16) or chondrosarcoma (n=5) treated by CIRT between May 2015 and April 2018. All the patients safely and successfully completed CIRT at SPHIC. The median follow-up time was 21.8 months (range, 7.2-39.2 months). The patient characteristics are shown in Table [1](#T1){ref-type="table"}. The median age of these patients was 64 years (range, 28-82 years). Tumors occurred in the sacrococcygeal region (n=19), the thoracic vertebra (n=1) or the pelvis (n=1). Eight patients received no previous treatments, and 13 patients had a locally recurrent tumor following previous resections (3 had one surgical resection and 10 had multiple resections). Among the patients with recurrent tumors, 6 received conventional photon radiotherapy in the past, and the median radiation dose was 54 Gy (range, 50-60 Gy). Eight patients had metal implants in their body due to tumor resection. All the patients had a gross tumor before CIRT. The median GTV was 512.7 ml (range, 142.6-2893.0 ml). The median prescribed total dose was 69 GyE (range, 57-80 GyE). The corresponding median equivalent dose calculated for a fraction of 2 GyE was 86.25 GyE (range, 65.53-120.0 GyE, α/β=2 GyE). The MRI images and dose distribution of a representative case are shown in Figure [1](#F1){ref-type="fig"}.

Outcome
-------

During the entire follow-up, 1 patient with sacral chordoma was evaluated as complete response (CR) at 1 year after CIRT (Figure [1](#F1){ref-type="fig"}). Three patients (14.3%) experienced progressive disease (PD). A patient with recurrent sacral chordoma who had received surgeries and conventional photon radiotherapy in the past was estimated as PD at 21.4 months after CIRT. In the patients with chondrosarcoma, a patient with primary chondrosarcoma and another with recurrent chondrosarcoma were assessed as PD at 32.2 and 10.8 months after CIRT, respectively. The 1-year and 2-year LC were 93.8% and 85.2%, respectively (Figure [2](#F2){ref-type="fig"}). Four patients (19.0%) experienced lung metastases. Two patients with chondrosarcoma developed lung metastases at 38.3 and 10.8 months after CIRT. Another two patients with primary sacral chordoma developed lung metastases after CIRT at 8.8 and 26.3 months, while they achieved local tumor control. The 1-year and 2-year PFS were 88.4% and 80.4%, respectively (Figure [3](#F3){ref-type="fig"}). Among all the patients, 20 patients were alive at the end of follow-up. A patient with primary sacral chordoma died at 27.6 months after CIRT due to lung metastases. The 1-year and 2-year OS were 100% (Figure [4](#F4){ref-type="fig"}).

Pain is the most common symptom that has a major impact on the quality of life of patients with chordoma or chondrosarcoma. Sixteen patients (76.2%) showed a decrease in pain at the end of follow-up. Among these patients, 6 (28.6%) had complete pain relief.

Toxicity
--------

Grade 1 acute skin toxicity occurred in 3 patients (14.2%). The most frequent toxicity was grade 1 myelosuppression in 7 patients (33.3%). None of the patients developed grade 2 or higher acute toxicity. No acute side effects of the gastrointestinal and genitourinary tract were observed (Table [2](#T2){ref-type="table"}). Overall, the adverse events of patients treated by CIRT were mild, and no severe late side effects were observed within the follow-up period.

Predictive parameters
---------------------

Using the log rank test, we evaluated the predictive value of age, metal implant status, treatment status, sex, dose, and GTV for LC, PFS, and OS (Table [3](#T3){ref-type="table"}). Factors, including age, metal implant status, treatment status, sex, and GTV were not significantly associated with the LC, PFS or OS. Although no statistically significant difference was found between the patients treated with a dose ≤70 GyE and those treated with a dose \>70 GyE, the patients who received a higher dose tended to have a better PFS (*p* = .19).

Discussion
==========

In most cases, patients with chordoma or chondrosarcoma had very large tumor at the time of the first diagnosis. Complete resection of the tumor remains a challenge, hence adjuvant radiotherapy is often recommended, and definitive radiotherapy might be an acceptable alternative to surgery for chordoma and chondrosarcoma [@B2], [@B5], [@B26]. Accumulated pre-clinical and clinical evidence demonstrates that CIRT has advantages in some radio-resistant malignancies, including chordoma and chondrosarcoma. However, CIRT has only been used for about 20 years [@B19]. And most of the clinical data are from few institutes in Japan and Germany. The lack of patient data resulting from limited access to carbon ion centers and treatment facilities makes a direct comparison difficult. More clinical data are crucial for future application of CIRT. In this retrospective study, we reported the initial experience of the patients with chordoma or chondrosarcoma treated by CIRT at our center. All the patients refused surgery or were deemed inoperable by the surgeon. The 1-year LC, PFS, and OS were 93.8%, 88.4%, and 100%, respectively, whereas the 2-year LC, PFS, and OS were 85.2%, 80.4%, and 100%, respectively.

To the best of our knowledge, this is the first clinical data from Chinese patients with extracranial chordoma and chondrosarcoma. The biological models applied in treatment planning are different between institutes. One of the main problems with carbon ions is the extreme difficulty in measuring relevant biological effects to produce accurate mathematical models that link dose and linear energy transfer (LET) spectra to clinical response [@B27]. Therefore, it is necessary to assess the treatment efficacy and toxicity between different carbon ion centers. As shown in Table [4](#T4){ref-type="table"}, several centers have used carbon ion or proton beams to treat patients with extracranial chordoma or chondrosarcoma in the past years. Data from the Heidelberg Ion Beam Therapy Center (HIT) indicated a 3-year LC rate of 53% and OS of 100% for 56 sacral chordoma patients treated by CIRT in combination with photon therapy or CIRT alone [@B28]. A total of 261 patients with extracranial chondrosarcoma or chordoma were treated with carbon ions at the National Institute of Radiological Sciences (NIRS) in Japan. The delivered total dose ranged from 64 GyE to 73.6 GyE. The reported 5-year LC rates were 53% and 77% for the chondrosarcoma and chordoma patients, respectively [@B9], [@B29]. CIRT is also available at the Hyogo Ion Beam Medical Center (HIBMC), Hyogo, Japan. Patients with sacral chordomas treated at HIBMC displayed a 3-year LC rate of 94% and OS of 83%, and the delivered total dose was 70.4 GyE [@B7]. Results from the Massachusetts General Hospital (MGH) also show good LC rates and OS for proton radiotherapy [@B30]. In some institutes, the patients were treated by surgery combined with or without photon radiotherapy. Data from the Mayo Clinic and Italy indicate a 5-year LC rate of about 55% for patients with chordoma [@B31], [@B32]. Although it is difficult to precisely compare the outcomes from multiple institutes due to the retrospective analyses and different patient characteristics, these results may indicate that treatment protocols containing particle therapy, especially CIRT, are expected to achieve better outcomes. Randomized clinical trials are warranted for further comparisons between carbon ion and proton therapy [@B33].

Since the follow-up was relatively short in the present study, short-term outcomes are taken into consideration when comparing our results with those of other centers. The reported cumulative 1-year LC rate was 99% for the chordoma patients treated with carbon ions at NIRS [@B29]. Matthias Uhl et al reported a 2-year LC rate of 76% and OS of 100% for chordoma patients [@B28]. In the present study, the 1-year LC and OS were 93.8% and 100%, respectively, whereas the 2-year LC and OS were 85.2% and 100%, respectively. It suggested that CIRT provide short-term efficient tumor control for patients with extracranial chordoma or chondrosarcoma.

Patients treated by CIRT at our center had negligible toxicity. Among all the patients, 3 (14.2%) had grade 1 acute skin side effects, and 7 (33.3%) had grade 1 myelosuppression. None of the patients developed grade 2 or higher acute and late side effects during the follow-up period. The results from HIT and GSI also indicated that no severe toxicity was detected in the patients [@B28], [@B34]. The data from NIRS showed that late grade 4 skin toxicity was observed in 2 patients, and late grade 3 peripheral nerve injuries occurred in 6 patients. The number of patients who had grade 3 or higher late toxicities accounted for only 4.8% [@B29]. All of these studies, along with our own, demonstrated that carbon ion radiotherapy can be considered safe.

Prognostic factors for patients with chordomas or chondrosarcoma treated with particle therapy have been investigated in previous studies (Table [5](#T5){ref-type="table"}). Taking into account the weakness of small patient sample and short follow-up time, we could not found any significant differences of LC and OS in consideration of age, mental implant status, sex, dose, and tumor volume. The results from GSI showed that younger age was significantly associated with an improved LC and OS for patients with chordoma or chondrosarcoma [@B34], [@B35]. Matthias Uhl et al from HIT demonstrated that males had a better 2-year LC rate than females (*p* = .03) [@B28]. M MIMA et al from HIBMC also reported that males showed a significantly better PFS (*p* = .029) [@B7]. The data from PSI showed that patients with chondrosarcoma had better LC (*p* = .014) and OS rates (*p* = .014) than those with chordoma [@B36]. In addition, smaller tumor and boost volume were correlated with better LC or OS. The results from the GSI group indicated that a boost volume ≤55 ml was significantly related to better LC rates for patients with chondrosarcoma (*p* = .039) [@B35], and a boost volume \<75 ml was significantly associated with an improved LC (*p* = .002) and OS rate (*p* = .030) for patients with chordoma [@B34]. The results from the NIRS group showed that chondrosarcoma patients with a tumor volume \<470 ml had better LC (*p* = .009) and OS (*p* = .0008) [@B9]. Damien C. Weber from PSI also reported that a GTV ≤25 mL was related to a better LC (*p* = .005) and OS (*p* = .01) [@B36]. The median volume of GTV in the current study was 513 ml (range, 143-2893 ml), which was larger than that of other reports [@B7], [@B28], [@B37], and 2 patients had significantly huge tumor (more than 2000 ml). The Japan and Germany studies showed good results, however, the patients had smaller tumor (the median clinical target volume was 370 ml (range, 47-1468 ml) in Chiba report; the median tumor size was 244 ml (range, 5-1188 ml) in HIT report) [@B28], [@B37]. And all the patients refused surgery or were deemed inoperable by the surgeon in our study. We evaluated the efficacy and toxicity of CIRT for large or even huge tumors that cannot be totally resected in the present study. Our initial experience would be valuable for the management of these large tumors.

Moreover, treatment for primary or recurrent tumor was the factor investigated. Treatment for recurrent chordoma resulted in a significantly lower LC (*p* = .001) [@B28] and OS (*p* = .025) [@B34]. In our study, we assessed 6 patients who were treated with CIRT as re-irradiation for tumor recurrence. The decreased tolerance of normal tissues, especially vital organs, often limited dose delivered to the tumor in the second course of radiotherapy. Hence, it remains a challenge to treat these patients who failed to respond to the first course of radiotherapy. The physical advantages of carbon ions allows more pronounced sparing of normal tissues [@B38]. The patients with recurrent tumor were safely treated with CIRT at our cancer. In spite of the small sample size, the data indicates that CIRT is a promising and safe treatment alternative for a subgroup of patients who require re-irradiation.

In summary, we reported the use of CIRT in the management of patients with extracranial chordoma or chondrosarcoma in this retrospective study. Although the number of patients is small and the follow-up time is relatively short, the results are encouraging. Patients with extracranial chordoma or chondrosarcoma treated with CIRT at our center achieved a favorable shot-term outcome without developing severe acute or late adverse events. Prospective trials with a longer follow-up time and a larger sample size are still warranted to confirm the local control and survival benefit of this promising treatment technology.
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![The MRI images and dose distribution of a representative case. A 60 years old female patient with sacral chordoma treated with CIRT at our center. **A.** Dynamic contrast enhanced T1-weighted (axial and sagital view) and T2-weighted MRI (sagital view) images performed before CIRT. **B.** Dynamic contrast enhanced T1-weighted (axial and sagital view) and T2-weighted MRI (sagital view) images performed one year after CIRT. **C.** A treatment plan for CIRT using 69 GyE in 23 fractions (the dose distribution and Dose-volume Histogram). Purple line: CTV. Yellow line: rectum. Light blue line: bladder. Green line: bowel. CIRT: carbon ion radiotherapy; GyE: gray equivalents.](jcav10p3315g001){#F1}
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![Progression free survival curve. PFS: Progression free survival.](jcav10p3315g003){#F3}
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###### 

Patient Characteristics

  Characteristics      No. (%)
  -------------------- ------------------------------
  Total                21 (100%)
  Age (years)          
  Median (range)       64 (28-82)
  Follow-up (months)   
  Median (range)       21.8 (7.2-39.2)
  Sex                  
  male                 10 (47.6%)
  female               11 (52.4%)
  Histology            
  chordoma             16 (76.2%)
  chondrosarcoma       5 (23.8%)
  Tumor site           
  Sacrococcygeal       19 (90.5%)
  Thoracic vertebra    1 (4.8%)
  Pelvis               1 (4.8%)
  Treatment            
  Primary              8 (38.1%)
  Recurrent            13 (61.9%)
  Prior radiotherapy   
  Yes                  6 (28.6%)
  No                   15 (71.4%)
  Metal implant        
  Yes                  8 (38.1%)
  No                   13 (61.9%)
  GTV (ml)             
  Median (range)       512.7 (142.6-2893.0)
  Total dose           
  Median (range)       69 GyE (57-80 GyE /18-25 Fx)
  EQD2 (α/β = 2)       
  Median (range)       86.25 GyE (65.53-120.0 GyE)

GyE: gray equivalents; GTV: gross tumor volume; Fx: fractions; EQD2: equivalent doses in 2 GyE fractions calculated using the LQ model.

###### 

Acute Toxicity

  Grade                    Grade 0      Grade 1      ≥Grade 2
  ------------------------ ------------ ------------ ----------
                           No. (%)      No. (%)      No. (%)
  Skin                     18 (85.7%)   3 (14.2%)    0 (0%)
  Myelosuppression         14 (66.7%)   7 (33.3%)    0 (0%)
  Gastrointestinal tract   21 (100%)    0 (0%)       0 (0%)
  Genitourinary tract      21 (100%)    0 (0%)       0 (0%)
  Total                                 10 (47.6%)   0 (0%)

###### 

The prognostic significance of the potential factors

  ------------------------------------------------------------------
  variable        Group        No. (100%)    *p*-value         
  --------------- ------------ ------------- ----------- ----- -----
  Age (year)      \<64\        10 (47.6%)\   .72         .76   .32
                  ≥64          11 (52.4%)                      

  Metal implant   Yes\         8 (38.1%)\    .72         .31   .44
                  No           13 (61.9%)                      

  Treatment       Primary\     8 (38.1%)\    .86         .33   .20
                  recurrent    13 (61.9%)                      

  Sex             Female\      11 (52.4%)\   .72         .98   .44
                  Male         10 (47.6%)                      

  Dose (GyE)      ≤70          14 (66.7%)    .71         .19   1

  \>70            7 (33.3%)                                    

  GTV (ml)        \<512.7      10 (47.6%)    .72         .48   .20

  ≥512.7          11 (52.4%)                                   
  ------------------------------------------------------------------

The prognostic significance of the potential factors was tested using the log rank test. A two-sided *p* \<0.05 was considered statistically significant. GyE: gray equivalents; GTV: gross tumor volume; LC: local control; PFS: progression free survival; OS: overall survival.

###### 

Comparison with other studies

  ----------------------------------------------------------------------------------------------------------------------------
  Institute        Year   No.   disease          treatment   TD, GyE            Follow-up, months   LC            OS
  ---------------- ------ ----- ---------------- ----------- ------------------ ------------------- ------------- ------------
  HIT [@B28]       2015   56    chordoma         C or C+PH   66 (60-74)         25 (range: NA)      2y: 76%\      2 y: 100%\
                                                                                                    3 y: 53%      3 y: 100%

  NIRS [@B9]       2017   73    ChSa             C           70.4 (64-73.6)     49.4 (6.4-146.4)    5 y: 53%      5 y: 53%

  NIRS [@B29]      2016   188   Chordoma         C           67.2 (64-73.6)     62 (6.8-147.5)      1 y: 99%\     1 y: NA\
                                                                                                    5 y: 77%      5 y: 81%

  HIBMC [@B7]      2014   23    chordoma         C or P      70.4               38 (7-78)           3 y: 94%      3 y: 83%

  MGH [@B30]       2015   126   chordoma         P           72.4 (46.3-83.6)   41 (range: NA)      5 y: 62%      5 y: 81%

  MC [@B31]        2005   52    chordoma         Surgery     NA                 93.6 (25.2-276)     5 y: 59%      5 y: 74%

  IOR/INT [@B32]   2010   130   Chordoma         Surgery     NA                 142 (76-210)        5 y: 52%      5 y: 78%

  Present          2018   21    ChSa /chordoma   C           69 (57-80)         21.8 (7.2-39.2)     1 y: 93.8%\   1 y: 100%\
                                                                                                    2 y: 85.2%    2 y: 100%
  ----------------------------------------------------------------------------------------------------------------------------

ChSa: chondrosarcoma; C: carbon ion radiotherapy; P: proton radiotherapy; PH: photon radiotherapy; TD: total dose; GyE: gray equivalents; LC: local control; OS: overall survival; HIT: Heidelberg Ion Beam Therapy Center; NIRS: National Institute of Radiological Sciences; HIBMC: Hyogo Ion Beam Medical Center; MGH: Massachusetts General Hospital; MC: Mayo Clinic; IOR: Istituto Ortopedico Rizzoli; INT: Istituto Nazionale Tumori.

###### 

Predictive factors investigated in other studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Institute       No.   Treatment          Factors been evaluated
  --------------- ----- ------------------ -----------------------------------------------------------------------------------------------------------------------------
  HIT [@B39]      101   primary, n=88\     age, sex, tumor volume, treatment (primary, recurrence)
                        recurrent, n=13    

  HIT [@B28]      56    primary, n=41\     age, dose, resection status, **sex^a^**, tumor volume, tumor location,**treatment (primary, recurrence)^a^**
                        recurrent, n=15    

  NIRS [@B9]      73    primary, n=55\     age, **histology^a^**, **tumor volume^a^**, tumor location, treatment (primary, recurrence, metastasis)
                        recurrent, n=17\   
                        Metastatic, n=3    

  NIRS [@B29]     188   primary, n=188     dose, level of proximal invasion, sex, tumor volume

  GSI [@B35]      79    primary, n=54\     **age^a^**, **boost volume^a^**, dose, sex, tumor grade, treatment (primary, recurrence)
                        recurrent, n=25    

  GSI [@B34]      155   primary, n= 101\   **age^a^**,**boost volume^a^**, dose, sex, **treatment (primary, recurrence)^a^**
                        recurrent, n=54    

  HIBMC [@B7]     23    primary, n=23      age, dose fractionation, ECOG PS, ion type, **sex^a^**, spacer placement, tumor volume

  PSI [@B36]      222   primary, n=171\    age, **compression of the brainstem or optic apparatus^a^**, **histology^a^,** number of weekly fractions, sex,**GTV^a^**,\
                        recurrent, n=51    treatment (primary, recurrence)

  Present study   21    primary, n=8\      age, metal implantation, sex, treatment (primary, recurrence), dose, tumor volume
                        recurrent, n=13    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

**^a^:** factors significantly correlated with LC, PFS, or OS (*p ≤*0.05). HIT: Heidelberg Ion Beam Therapy Center; NIRS: National Institute of Radiological Sciences; GSI: Society for Heavy Ion Research in Darmstadt; HIBMC: Hyogo Ion Beam Medical Center; PSI: Center for Proton Therapy, Paul Scherrer Institute; GTV: gross tumor volume.
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